98%
921
2 minutes
20
Anemia and other hematological abnormalities are common in patients with Sheehan's syndrome. The response of these abnormalities to replacement of thyroxine and glucocorticoids is not clear. The aim of the present study was to document the profile of hematological abnormalities and response to treatment in patients with Sheehan's syndrome. Forty patients of Sheehan's syndrome and an equal number of age and parity matched healthy controls were studied for prevalence of hematological abnormalities. Hemoglobin concentration, hematocrit, red cell, white cell and platelet count were significantly decreased in patients with Sheehan's syndrome compared to controls. Frequency of anemia, leucopenia, thrombocytopenia and pancytopenia was significantly higher in these patients compared to controls. After achieving euthyroid and eucortisol state, there was a complete recovery of these hematological abnormalities. We conclude that anemia and other cytopenias are common in patients with Sheehan's syndrome and replacement with thyroxine and glucocorticoids results in complete recovery of these abnormalities.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1007/s11102-010-0255-2 | DOI Listing |
PLoS Pathog
September 2025
Department of Virology, Immunology, and Microbiology, Boston University Chobanian & Avedisian School of Medicine, Boston, Massachusetts, United States of America.
While human autopsy samples have provided insights into pulmonary immune mechanisms associated with severe viral respiratory diseases, the mechanisms that contribute to a clinically favorable resolution of viral respiratory infections remain unclear due to the lack of proper experimental systems. Using mice co-engrafted with a genetically matched human immune system and fetal lung xenograft (fLX), we mapped the immunological events defining successful resolution of SARS-CoV-2 infection in human lung tissues. Viral infection is rapidly cleared from fLX following a peak of viral replication, histopathological manifestations of lung disease and loss of AT2 program, as reported in human COVID-19 patients.
View Article and Find Full Text PDFQual Manag Health Care
August 2025
Author Affiliations: St. Luke's Radiation Oncology Network, SLRON Rathgar, Dublin, Ireland (Ms O'Shea, Prof Brennan, Prof Gillham, and Dr Daly); Coombe Women & Infants University Hospital, CWIUH Dublin, Ireland (Ms O'Shea, Prof Sheehan, and Dr Popivanov); Naas General Hospital, NGH Naas, Co. Kildare
Background And Objectives: This paper defines quality improvement (QI), describes the differences and connections among QI, clinical audit/quality assurance, and clinical research, highlights the importance of strong organizational governance for QI, and provides a simplified, evidence-based QI methodology that can be readily used by health care staff.
Methods: The authors draw on their diverse QI experiences, encompassing a university maternity hospital, a radiation oncology specialist center, an acute general hospital, senior health care management, and academia. This demonstrates the feasibility of implementing QI in diverse health care settings and by all members of the multidisciplinary team.
Eur Neuropsychopharmacol
August 2025
Outpatient Clinic Pharmacogenetics, Parnassia Psychiatric Institute, Amsterdam, the Netherlands; Department of Psychological Medicine Institute of Psychiatry, Psychology and Neuroscience- King's College London, London, UK; St. John's National Academy of Health Sciences, Bangalore, India.
We conducted a systematic review and meta-analysis to estimate the efficacy of pharmacogenetic (PGx)-guided antidepressant treatment compared to treatment as usual (TAU) on functional outcomes and quality of life (QoL) in people with anxiety and affective disorders. A PRISMA-compliant systematic search was performed up to 26/06/2025 to identify relevant prospective, randomised controlled trials (RCTs) in seven databases. The revised tool for Risk of Bias (RoB2) was used to assess the methodological qualities of the included studies (PROSPERO CRD42024518683).
View Article and Find Full Text PDFAnn 3D Print Med
August 2025
Institute for Applied Life Sciences, University of Massachusetts Amherst, Amherst, Massacusetts, United States.
Polymer additive manufacturing (AM) is a powerful method for medical device prototyping, producing low-cost medical devices for resource limited settings and patient-specific customization. Plastic medical devices created with AM must undergo sterilization prior to in vivo experiments or use with patients. While prior studies have verified the feasibility and safety of sterilization of such devices, the impact on mechanical performance has not been studied.
View Article and Find Full Text PDFJ Subst Use Addict Treat
August 2025
Upstream Lab, MAP Centre for Urban Health Solutions, Li Ka Shing Knowledge Institute, Unity Health Toronto, Toronto, ON, Canada; Institute of Health Policy, Management and Evaluation, University of Toronto, Toronto, ON, Canada; Department of Family and Community Medicine, St. Michael's Hospital, Tor
Introduction: Addiction consultation services are hospital-based specialist programs designed to support the care of patients with substance use disorders (SUDs). This study aimed to: (1) describe service volumes and patient demographics for a pilot addiction consultation program, (2) compare clinical outcomes between patients seen prior to and after program implementation, and (3) explore provider perceptions, referral patterns, and clinical practice.
Methods: Using the RE-AIM framework, we conducted a formative multi-method evaluation at a tertiary care hospital.